Doxtator
Oct 26, 6:46 PM
Deep dive on
$AVTX over the weekend. We shouldn't drag
$AVTX down on
$ABBV's Phase 3 results. Abdakibart has stronger IL-1β binding affinity, a longer half-life, better subcutaneous bioavailability, and a prior HS trial targeting IL-1α failed to show any benefit over placebo. Further, meta-analysis data in gout, another chronic inflammatory disease, supports possible higher IL-1β efficacy over a combination IL-1α/1β approach.
The selloff in
$AVTX to basically cash has completely discounted the clinical pipeline of a possible best-in-class HS asset. We still need Phase 3 data and trial design. But the LOTUS Phase 2 numbers showed remarkable agreement between the trial arms, especially compared to lutikizumab, where the arm results varied widely, and the strongest-performing arm may have been more noise than signal.
Full report: https://helixdataanalytics.com/research-avtx-abdakibart.html
